Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

View Full Paper
Ask AI
Bookmark
Share

Authors

JAJeremy S. AbramsonHHHuiqiang HuangWKWon-Seog Kim

Discussion

Loading...

Member takes

Overview

Randomized trial shows better survival in DLBCL patients treated with glofitamab plus GemOx, indicating lasting benefits compared to rituximab plus GemOx.

Key Points

  • Glofitamab plus GemOx treatment demonstrated significantly improved overall survival versus R-GemOx.
  • After three years, overall survival was 25.5 months for Glofit-GemOx compared to 12.5 months for R-GemOx.
  • Assessment of landmark analyses indicated a sustained complete response rate in Glofit-GemOx patients at 24 months.
  • Long-term safety profile aligns with existing known risks, highlighting manageable adverse events including cytokine release syndrome.

Cite This Study

Abramson et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d52fhttps://doi.org/10.1182/blood-2025-5519
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups2025
  2. 2Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States2025
  3. 3Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  4. 4Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  5. 5Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis2025